Table 4 Serum neutralization activity against Indiana and Cocal VSV.G.

From: Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers

Animal ID

 

AS304

AT777

AU018

AU955

AU989

Vaccine Group

Week

*VSV.GIn

*VSV.GCo

**IgG

*VSV.GIn

*VSV.GCo

**IgG

*VSV.GIn

*VSV.GCo

**IgG

*VSV.GIn

*VSV.GCo

**IgG

*VSV.GIn

*VSV.GCo

**IgG

IDLV-UFO.750

0

<100

<100

1

<100

<100

11

<100

<100

2

<100

538

3

<100

361

4

(VSV.GIn)

 

6

20663

299

1760

17977

190

4962

10476

<100

942

17,529

136

2631

30487

380

3030

IDLV-UFO.750

37

3165

112

878

4316

272

1773

1247

104

942

29,839

218

5329

28936

907

6310

(VSV.GCo)

 

39

>312,500

211,659

29,368

>312,500

64,286

38,192

>312500

67,694

10791

>312,500

64,960

89779

>312500

147464

77548

 

43

88,926

51,649

16,205

144,196

30,027

14,507

41402

22,424

6680

121,742

52,326

28796

82985

38167

14375

  1. *Values are expressed as ID50, corresponding to the serum dilution at which relative luminescence units (RLU) were reduced by 50% compared to virus-only control wells.
  2. **Values are indicated as concentration (ng/ml) of specific anti-ConSOSL.UFO IgG.